4.40

1.79% -0.08

After Hours: 4.40

Maravai Lifesciences Holdings Inc (MRVI)

Overview News Price History Option Chain Financials Why MRVI Down? Discussions Forecast

Maravai Lifesciences Holdings Inc stock is traded at $4.40, with a volume of 2.22M. It is down -1.79% in the last 24 hours and up +19.24% over the past month. Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.

Previous Close:

$4.48

Open:

$4.48

24h Volume:

2.22M

Relative Volume:

1.08

Market Cap:

$649.03M

Revenue:

$185.74M

Net Income/Loss:

$-230.76M

P/E Ratio:

-4.857

EPS:

-0.9059

Net Cash Flow:

$-70.72M

1W Performance:

+6.02%

1M Performance:

+19.24%

6M Performance:

+17.33%

1Y Performance:

+91.72%

1-Day Range:

$4.3413

$4.52

1-Week Range:

$4.00

$4.52

52-Week Range:

$1.99

$4.995

Maravai Lifesciences Holdings Inc Stock (MRVI) Company Profile

Name

Maravai Lifesciences Holdings Inc

Sector

Healthcare (1108)

Industry

Biotechnology (618)

Phone

(858) 546-0004

Address

10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO

Employee

416

Twitter

Next Earnings Date

2026-05-07

Latest SEC Filings

MRVI's Discussions on Twitter

Compare MRVI vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MRVI Maravai Lifesciences Holdings Inc	4.40	660.83M	185.74M	-230.76M	-70.72M	-0.9059
VRTX Vertex Pharmaceuticals Inc	434.52	110.03B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	638.88	67.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	806.46	50.76B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	297.45	40.12B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	151.56	32.68B	742.00K	-1.37B	-1.07B	-7.0731

Maravai Lifesciences Holdings Inc Stock (MRVI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-26-25	Downgrade	Robert W. Baird	Outperform → Neutral
Dec-19-24	Initiated	Guggenheim	Neutral
Dec-05-24	Downgrade	Goldman	Neutral → Sell
Nov-14-24	Initiated	Wolfe Research	Peer Perform
Nov-08-24	Downgrade	William Blair	Outperform → Mkt Perform
Aug-28-24	Initiated	Wells Fargo	Overweight
Aug-13-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Apr-10-24	Initiated	Craig Hallum	Buy
Dec-12-23	Upgrade	BofA Securities	Neutral → Buy
Aug-08-23	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
May-23-23	Downgrade	Credit Suisse	Outperform → Neutral
May-09-23	Downgrade	Goldman	Buy → Neutral
Jan-05-23	Downgrade	UBS	Buy → Neutral
Dec-14-22	Initiated	Deutsche Bank	Buy
Dec-07-22	Initiated	RBC Capital Mkts	Outperform
Nov-03-22	Downgrade	BofA Securities	Buy → Neutral
Aug-25-22	Initiated	Credit Suisse	Outperform
Aug-05-21	Resumed	Credit Suisse	Outperform
Dec-16-20	Initiated	KeyBanc Capital Markets	Overweight
Dec-15-20	Initiated	BofA Securities	Buy
Dec-15-20	Initiated	Credit Suisse	Outperform
Dec-15-20	Initiated	Goldman	Buy
Dec-15-20	Initiated	Jefferies	Buy
Dec-15-20	Initiated	Robert W. Baird	Outperform
Dec-15-20	Initiated	Stifel	Buy
Dec-15-20	Initiated	William Blair	Outperform
Dec-14-20	Initiated	UBS	Buy

View All

Maravai Lifesciences Holdings Inc Stock (MRVI) Latest News

May 22, 2026

Maravai (MRVI) officer granted 5,006 ESPP shares at $1.79 - Stock Titan

May 22, 2026

Maravai Lifesciences (NASDAQ: MRVI) counsel gets 776 ESPP shares - Stock Titan

May 22, 2026

May 18, 2026

Maravai LifeSciences To Attend The Jefferies Global Healthcare Conference - Business Wire

May 18, 2026

Maravai LifeSciences: Better Earnings Drive Gains That Ought To Be Sustainable (MRVI) - Seeking Alpha

May 18, 2026

May 17, 2026

Maravai LifeSciences Holdings, Inc.Class A common stock (NQ: MRVI - The Chronicle-Journal

May 17, 2026

Maravai LifeSciences Holdings, Inc. Sued for Securities Law Viola - The National Law Review

May 17, 2026

May 16, 2026

Maravai LifeSciences Holdings (MRVI) price target increased by 23.91% to 5.81 - MSN

May 16, 2026

May 15, 2026

12 West Capital Amends 13G, Holds 7.26M Shares in Maravai (MRVI) - Stock Titan

May 15, 2026

Maravai LifeSciences Q1 Turnaround Spurs Rethink Of CleanCap Driven Outlook - Sahm

May 15, 2026

May 14, 2026

How The Maravai LifeSciences (MRVI) Narrative Is Shifting With New Targets And 2026 Guidance - Yahoo Finance

May 14, 2026

Maravai LifeSciences stock (US56600D1072): Q1 turnaround and CleanCap momentum draw fresh investor a - AD HOC NEWS

May 14, 2026

Stuart Feldman-led group reports 9.21% stake in Maravai (MRVI) - Stock Titan

May 14, 2026

May 12, 2026

Millennium group lists 4.9% holding in Maravai (NASDAQ: MRVI) on 13G - Stock Titan

May 12, 2026

TradingKey - TradingKey

May 12, 2026

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Q1 2026 Earnings Call Transcript - Insider Monkey

May 12, 2026

May 11, 2026

Maravai Lifesciences Signals Turnaround in Earnings Call - TipRanks

May 11, 2026

May 09, 2026

Maravai (MRVI) Q1 2026 Earnings Transcript - AOL.com

May 09, 2026

All you need to know about Maravai LifeSciences (MRVI) rating upgrade to buy - MSN

May 09, 2026

Maravai LifeSciences Holdings, Inc. Q1 2026 Financial Results, Risks, and Forward-Looking Statements - Minichart

May 09, 2026